Potassium Chloride Sustained Release Tablets

Potassium is the main cation in cells, with a concentration of 150-160 mmol/L; while the main cation outside cells is sodium ion, with a potassium concentration of only 3.5-5 mmol/L. The body mainly relies on Na-K±ATPase on the cell membrane to maintain the difference in K and Na concentrations in cells. The acid-base balance in the body affects potassium metabolism. For example, when acidosis occurs, H enters the cell. In order to maintain the potential difference of the cell, K is released outside the cell, causing or aggravating hyperkalemia. Metabolic disorders can also affect acid-base balance. The normal intracellular and extracellular potassium ion concentration and concentration difference are closely related to some important functions of cells, including maintaining carbohydrate metabolism, glycogen storage, protein metabolism, intracellular osmotic pressure and acid-base balance, myocardial excitability and conductivity; maintaining normal skeletal muscle tension and nerve impulse conduction, and increasing the tension of intestinal, uterine and bronchial smooth muscles.

The main ingredient of this product and its chemical name: potassium chloride.

This product is white or slightly yellow granules.

1 Treatment of hypokalemia Hypokalemia caused by various reasons, such as insufficient food intake, vomiting, severe diarrhea, and the use of potassium-excreting diuretics. Hypokalemic familial periodic paralysis, long-term use of glucocorticoids, and supplementation of hypertonic glucose, etc. 2 Prevention of hypokalemia When the patient has potassium loss, especially if hypokalemia is harmful to the patient (such as patients using digitalization), preventive potassium salt supplementation is required, such as eating very little, severe or chronic diarrhea, long-term use of adrenocortical hormones, potassium-losing nephropathy, and Bartter syndrome, etc. 3 Digitalis poisoning causes frequent, multi-source premature beats or rapid arrhythmias.

Adults take 0.5g to 1g each time, 2 to 4 times a day, after meals, and adjust the dose according to the condition. The maximum daily dose for adults is 6g. For those who have gastrointestinal reactions to oral tablets, oral solution can be used instead, diluted in cold boiled water or beverages for oral administration.

1. Oral administration may occasionally cause gastrointestinal irritation symptoms, such as nausea, vomiting, throat discomfort, chest pain (esophageal irritation), abdominal pain, diarrhea, and even peptic ulcer and bleeding. It is more likely to occur when the patient is fasting, takes a large dose, or has existing gastrointestinal diseases. 2. Hyperkalemia. It is prone to occur when the patient is overdosed or has existing renal damage. It manifests as weakness, fatigue, numbness of the hands, feet, lips, and mouth, unexplained anxiety, confusion, dyspnea, slow heart rate, arrhythmia, conduction block, and even cardiac arrest. The electrocardiogram shows a high and sharp T wave, and the P-R interval gradually becomes prolonged. The P wave disappears, the QRS wave becomes wider, and a sine wave appears. Once hyperkalemia occurs, it should be treated immediately. (1) Stop potassium supplementation immediately, avoid potassium-containing diets, drugs, and potassium-sparing diuretics. (2) Intravenous infusion of high-concentration glucose injection and insulin to promote the entry of K into cells, 10%~25% glucose injection 300~500ml per hour. Add 10 units of regular insulin to every 20g of glucose. (3) If metabolic acidosis is present, 5% sodium bicarbonate injection should be used immediately. For those without acidosis, 11.2% sodium lactate injection can be used, especially for those with widened QRS waves. (4) Use calcium to counteract the cardiac toxicity of K. When the electrocardiogram shows P wave deficiency, widened QRS waves, and arrhythmias, and digitalis drugs are not used, 10% calcium gluconate injection 10ml can be given, intravenously for 2 minutes, and repeated every 2 minutes if necessary. (5) Oral potassium-lowering resin to block intestinal K absorption and promote intestinal K excretion. (6) Severe hyperkalemia accompanied by renal failure. Hemodialysis or peritoneal dialysis can be performed, and hemodialysis has a better effect and faster speed in removing K. (7) Use loop diuretics and supplement with normal saline if necessary.

Hyperkalemia; patients with scanty urine output and urinary retention.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: The kidneys of the elderly have a reduced ability to clear potassium, and are more likely to develop hyperkalemia when using potassium salts. Follow-up checks of blood potassium should be performed during medication.

1. Adrenal glucocorticoids, especially those with more obvious mineralocorticoid effects, adrenal mineralocorticoids and adrenocorticotropic hormone (ACTH), can promote urinary potassium excretion, and when used together, the efficacy of potassium salts is reduced. 2. Anticholinergic drugs can aggravate the gastrointestinal irritation of oral potassium salts, especially potassium chloride. 3. Non-steroidal anti-inflammatory analgesics aggravate the gastrointestinal reactions of oral potassium salts. 4. When using stored blood (30mmol/L of potassium for less than 10 days of storage, 65mmol/L of potassium for more than 10 days of storage), taking potassium-containing drugs and potassium-sparing diuretics, the chance of hyperkalemia increases, especially in patients with renal impairment. 5. Angiotensin-converting enzyme inhibitors and cyclosporine can inhibit aldosterone secretion and reduce urinary potassium excretion. Hyperkalemia is prone to occur when used together. 6. Heparin can inhibit the synthesis of aldosterone and reduce urinary potassium excretion. Hyperkalemia is prone to occur when used together; in addition, heparin can increase the chance of gastrointestinal bleeding. 7. Sustained-release potassium salts can inhibit the intestinal absorption of vitamin B12.

Keep tightly closed.

0.5g

24 months.

Hangzhou Minsheng Pharmaceutical Co., Ltd.

• Founded in:

  1963-11-29

• Address:

  No. 36, Linping Avenue, Donghu Street, Linping District, Hangzhou City, Zhejiang Province

• Tax NO.:

  913301101430685558

• Registered Funds:

  88.97 million yuan

• Website:

  Log in to view

• Email:

  Log in to view